Epizyme, Inc. (EPZM) saw a big move last session, as the company’s shares fell by nearly 10% on the day. The move came on pretty good volume too with far more shares changing hands than in a normal session. This stock, trading at a volatile range of $21.94–$25.45 in the past one-month time frame, showed a sharp decline on Friday at $23.02.
On Mar 12, the company reported its fourth quarter results where the revenues declined year over year.
Although this slump was obviously disappointing and the med – biomed/gene company has not seen any positive revisions, however its current year earnings consensus has moved higher over the past few weeks. This suggests that the recent slump might be a temporary blip on the radar for EPZM. So make sure to keep an eye on this stock going forward to see if yesterday’s price decline is confirmed by more weakness, or if it can rebound in the weeks ahead.
EPZM currently has a Zacks Rank #3 (Hold).
A better-ranked stock in the med – biomed/gene sector is ANI Pharmaceuticals, Inc. (ANIP), which currently carries a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Be the first to comment